1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Sanofi Scores Clinical Win In Sixth Disease For Dupixent

First Biologic To Reduce Itch And Skin Lesions From Prurigo Nodularis

 
• By Kevin Grogan

The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.

six balloon
• Source: Alamy

Dupixent's status as a pipeline in a product has been further cemented by positive data in patients with prurigo nodularis, the sixth disease that Sanofi's blockbuster has succeeded in at Phase III.

Sanofi and partner Regeneron Pharmaceuticals, Inc. have announced results from the Phase III PRIME2 trial evaluating Dupixent (dupilumab) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.